Additionally, another exception occurred while executing the custom error page for the first exception. The information you’re looking for cannot be found, it may be temporarily unavailable or permanently removed. Mefloquine lariam and chloroquine Chloroquine retroviral transfection Vision changes/loss of vision There is a chance that retinal damage will occur while taking hydroxychloroquine Plaquenil or chloroquine Aralen. This is called known as hydroxychloroquine retinopathy. I have been on plaquenil since October of 2013. I started on 50 mg to avoid side effects then upped to 100 and finally to 150. I did experience the GI side effects but they have mostly passed. I do have horrible constipation though and I am not sure if this is due to the plaquenil or to the disease itself. All I know is its a new symptom for me. Hydroxychloroquine, sold under the brand name Plaquenil Sanofi-Aventis, is an antimalarial drug that has gained widespread use in treating various autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. 1 By some estimates, more than 150,000 patients are on long-term therapy with this medication in America alone. 2 Retinal toxicity associated with HCQ use is. If the problem continues, please visit our support portal. Try refreshing the page, or returning to the homepage. Plaquenil oct changes Protecting your eyesight when taking Plaquenil Lupus., Plaquenil causing mood changes and depression? Take hydroxychloroquine with neurontinPlaquenil baseline examen Dec 04, 2014 These changes have been correlated with abnormalities on coexisting SD-OCT for the same patient. Due to these FAF changes being quite subtle, clinician dependent, and inadequate in detecting subclinical HCQ retinopathy, FAF is not considered to be reliable as a primary screening modality. Hydroxychloroquine retinopathy A review of imaging. Multimodal Imaging in Plaquenil Toxicity. New Plaquenil Guidelines -. Results SD-OCT images demonstrated loss of photoreceptor inner segment/outer segment IS/OS junction and a downward “sink-hole” displacement of inner retinal structures in areas of hydroxychloroquine toxicity corresponding to HVF 10-2 defects and ophthalmoscopic clinical examination findings. Progression of SD-OCT changes after drug cessation. Morphological SD-OCT changes in each group after drug cessation is shown in Fig. 2. An interval change in SD-OCT appearance suggesting structural progression of toxicity was observed in 75 % Early, 71 % Obvious, and 100 % of Severe eyes. Although rare, Plaquenil can cause significant toxicity to the eye with prolonged use. Also, Plaquenil may have various systemic side effects that are not related to the eyes. These too are rare and include nerve weakness, hallucinations, psoriasis and changes in hair color. The eye complications are the most serious and worrisome.